LLY vs ABBV
By Alex · Tickerpine
Eli Lilly and Company vs AbbVie Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ABBV |
|---|---|---|
| Price | $1,208.12 | $253.35 |
| Market cap | $1.08T | $447.62B |
| P/E ratio | 42.9 | 123.6 |
| ROE | 107.46% | — |
| Profit margin | 34.99% | 5.79% |
| Revenue growth | 55.50% | 12.40% |
| Dividend yield | 0.57% | 2.73% |
| Beta | 0.52 | 0.31 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ABBV in plain English
- LLY is the bigger company — about 2.4× the market cap of ABBV.
- LLY is cheaper on earnings (P/E 42.9 vs 123.6).
- LLY is growing revenue faster (56% vs 12%).
- ABBV has the higher dividend yield (2.73% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.